The National Comprehensive Cancer Network® (NCCN®) recently updated their guidelines1 for genetic testing in prostate cancer. Data presented at ASCO 2017 showed that the existing guidelines were too narrow.
The new guidelines recommend consideration of germline genetic testing in the following patients:
Germline genetic testing in castrate-resistant prostate cancer may help guide medical management such as:
1Referenced with permission from the NCCN: Prostate Cancer. Version 1.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed February 26, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org.
The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.